IP Library › Granted Patent US 10,588,915
Granted Patent B2
US 10,588,915 · App. 16/019,253 · Granted Mar 17, 2020

Compositions and methods for the treatment of meibomian gland dysfunction

Inventors: Yair Alster (Tel Aviv, IL); Omer Rafaeli (Udim, IL); K. Angela MacFarlane (Menlo Park, CA); Cary Reich (Santa Barbara, CA); Shimon Amselem (Rehovot, IL); Doron Friedman (Carme-Yosef, IL)
Assignee: AZURA OPHTHALMICS LTD.
A61K31/60A61K8/22A61K8/23A61K9/0048A61K9/06A61K31/122A61K31/17A61K31/19A61K31/327A61K31/4015A61K31/555A61K33/04A61K35/04A61K9/0014
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,588,915
App. No.
16/019,253
Granted
Mar 17, 2020
Kind
B2
Abstract

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Claims (14)

1. A method for treating meibomian gland dysfunction in a patient in need thereof, comprising topically administering to the patient a composition that reaches the eyelid margin of the patient, wherein the composition comprises a therapeutically-effective amount of benzoyl peroxide in an ophthalmically-acceptable carrier and wherein the meibomian gland dysfunction is characterized by keratinized obstruction.

2. The method of claim 1 , wherein composition is topically administered to the patient until the keratinized obstruction is relieved.

3. The method of claim 1 , wherein composition is topically administered to the patient periodically after relieving the keratinized obstruction.

4. The method of claim 1 , wherein the topical administration is a single administration.

5. The method of claim 1 , wherein the topical administration is a periodic administration.

6. The method of claim 5 , wherein the periodic administration is once a day.

7. The method of claim 5 , wherein the periodic administration is two times a day.

8. The method of claim 1 , wherein the composition for topical administration is a semi-solid.

9. The method of claim 1 , wherein the composition for topical administration is homogenous.

10. The method of claim 1 , wherein the composition for topical administration is a dispersion.

11. The method of claim 1 , wherein the composition for topical administration is hydrophilic.

12. The method of claim 1 , wherein the composition for topical administration has an oleaginous base.

13. The method of claim 1 , wherein the ophthalmically-acceptable carrier comprises at least one ophthalmically-acceptable excipient.

14. The method of claim 1 , wherein the administration of the composition results in enhanced meibum production.

Assignments (2)
CHANGE OF NAME Recorded Jan 16, 2020
From: M.G. THERAPEUTICS LTD.
To: AZURA OPHTHALMICS LTD.
Reel/Frame 051624/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2018
From: ALSTER, YAIR; RAFAELI, OMER; MACFARLANE, KIRSTEN ANGELA; REICH, CARY; AMSELEM, SHIMON; FRIEDMAN, DORON
To: M.G. THERAPEUTICS LTD.
Reel/Frame 046447/0684 →
Continuity (4)
Continuation 15269833 · Sep 19, 2016
Continuation 14732622 · Jun 5, 2015
Provisional Application 62065716 · Oct 19, 2014
Related Publication 20190125766A1 · May 2, 2019
Cited By (9)
US 12,213,964 US 12,257,263 US 12,364,685 US 12,427,158 US 12,447,162 US 12,458,661 US 12,502,377 US 12,661,339 US 12,697,352